Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Resmed Inc (RMD)

Resmed Inc (RMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,379,980
  • Shares Outstanding, K 144,915
  • Annual Sales, $ 2,957 M
  • Annual Income, $ 621,670 K
  • 60-Month Beta 0.28
  • Price/Sales 10.10
  • Price/Cash Flow 34.10
  • Price/Book 11.15
Trade RMD with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.20
  • Number of Estimates 4
  • High Estimate 1.27
  • Low Estimate 1.13
  • Prior Year 1.21
  • Growth Rate Est. (year over year) -0.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
193.19 +8.49%
on 11/02/20
224.24 -6.53%
on 11/09/20
+17.66 (+9.20%)
since 10/30/20
3-Month
165.72 +26.48%
on 09/21/20
224.24 -6.53%
on 11/09/20
+29.37 (+16.30%)
since 08/28/20
52-Week
108.85 +92.56%
on 03/23/20
224.24 -6.53%
on 11/09/20
+60.00 (+40.11%)
since 11/29/19

Most Recent Stories

More News
Baxter (BAX) Announces Site Expansion to Improve Patient Care

Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.

BAX : 76.07 (+0.13%)
HOLX : 69.13 (-0.55%)
RMD : 209.60 (-0.02%)
TMO : 464.98 (+2.55%)
Here's Why You Should Invest in Syneos Health (SYNH) Now

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.

HOLX : 69.13 (-0.55%)
RMD : 209.60 (-0.02%)
TMO : 464.98 (+2.55%)
SYNH : 65.84 (-1.23%)
Is ResMed (RMD) Stock Outpacing Its Medical Peers This Year?

Is (RMD) Outperforming Other Medical Stocks This Year?

RMD : 209.60 (-0.02%)
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.

RMD : 209.60 (-0.02%)
ALGN : 481.29 (+1.22%)
TMO : 464.98 (+2.55%)
BIO : 538.50 (+0.64%)
LabCorp (LH) Expands in New Jersey With Clinical Trial Deal

LabCorp's (LH) Patient Direct offering will be used here to help in bringing suitable clinical trials to eligible patients directly.

RMD : 209.60 (-0.02%)
LH : 199.84 (-0.08%)
ALGN : 481.29 (+1.22%)
TMO : 464.98 (+2.55%)
Here's Why You Should Add ResMed (RMD) to Your Portfolio

Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

HOLX : 69.13 (-0.55%)
RMD : 209.60 (-0.02%)
ALGN : 481.29 (+1.22%)
TMO : 464.98 (+2.55%)
Quest Diagnostics (DGX) Grows on Two New Lab-Service Pacts

Quest Diagnostics (DGX) is moving ahead in terms of its growth strategy, which consists of five elements.

DGX : 123.98 (-0.66%)
RMD : 209.60 (-0.02%)
ALGN : 481.29 (+1.22%)
TMO : 464.98 (+2.55%)
Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm

Lower sales of Phibro's (PAHC) Performance Products arm's copper-based products raise concerns.

RMD : 209.60 (-0.02%)
ALGN : 481.29 (+1.22%)
TMO : 464.98 (+2.55%)
PAHC : 18.89 (-2.78%)
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.

ILMN : 322.09 (+1.60%)
RMD : 209.60 (-0.02%)
ALGN : 481.29 (+1.22%)
TMO : 464.98 (+2.55%)
Tandem Diabetes' (TNDM) Insulin Pump Approved by Health Canada

Tandem Diabetes' (TNDM) t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology cleared for use in Canada post the receipt of Health Canada approval.

MDT : 113.70 (-0.78%)
RMD : 209.60 (-0.02%)
TMO : 464.98 (+2.55%)
TNDM : 93.88 (+3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ResMed Inc. is a world-leading connected health company with cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions....

See More

Key Turning Points

2nd Resistance Point 212.65
1st Resistance Point 211.12
Last Price 209.60
1st Support Level 207.97
2nd Support Level 206.35

See More

52-Week High 224.24
Last Price 209.60
Fibonacci 61.8% 180.16
Fibonacci 50% 166.54
Fibonacci 38.2% 152.93
52-Week Low 108.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar